Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this research study to find out if the drug trametinib in combination with
ruxolitinib is safe, tolerable and has beneficial effects in people who has certain type of
cancers including the type that you have. Patients with RAS mutant colorectal cancer and
pancreatic adenocarcinoma are invited to participate in this study. This is the first time
that both trametinib and ruxolitinib are studied in combination. Trametinib is marketed in
several countries with the brand name Mekinist® for the treatment of melanoma (a type of skin
cancer). Trametinib has been studied extensively in cancer and has been tested in many
patients. Ruxolitinib is an oral inhibitor of JAK1 and JAK2 tyrosine kinases and is approved
for treatment of adult polycythemia vera and myelofibrosis. Ruxolitinib has been studied
extensively in many patients.